Perfusion CT Imaging of Brain Tumors: An Overview

References

1. 1.↵
   1. Folkman J

   . The role of angiogenesis in tumor growth. Semin Cancer Biol 1992; 3: 65–71

   PubMed
2. 2.↵
   1. Jain RK,
   2. Munn LL,
   3. Fukumura D

   . Dissecting tumour pathophysiology using intravital microscopy. Nat Rev Cancer 2002; 2: 266–76

   CrossRefPubMedWeb of Science
3. 3.↵
   1. Law M,
   2. Young RJ,
   3. Babb JS,
   4. et al

   . Gliomas: predicting time to progression or survival with cerebral blood volume measurements at dynamic susceptibility-weighted contrast-enhanced perfusion MR imaging. Radiology 2008; 247: 490–98

   CrossRefPubMedWeb of Science
4. 4.↵
   1. Roberts HC,
   2. Roberts TP,
   3. Brasch RC,
   4. et al

   . Quantitative measurement of microvascular permeability in human brain tumors achieved using dynamic contrast-enhanced MR imaging: correlation with histologic grade. AJNR Am J Neuroradiol 2000; 21: 891–99

   Abstract/FREE Full Text
5. 5.↵
   1. Law M,
   2. Yang S,
   3. Babb JS,
   4. et al

   . Comparison of cerebral blood volume and vascular permeability from dynamic susceptibility contrast-enhanced perfusion MR imaging with glioma grade. AJNR Am J Neuroradiol 2004; 25: 746–55

   Abstract/FREE Full Text
6. 6.↵
   1. Ellika SK,
   2. Jain R,
   3. Patel SC,
   4. et al

   . Role of perfusion CT in glioma grading and comparison with conventional MR imaging features. AJNR Am J Neuroradiol 2007; 28: 1981–87

   Abstract/FREE Full Text
7. 7.↵
   1. Jain R,
   2. Ellika SK,
   3. Scarpace L,
   4. et al

   . Quantitative estimation of permeability surface-area product in astroglial brain tumors using perfusion CT and correlation with histopathologic grade. AJNR Am J Neuroradiol 2008; 29: 694–700

   Abstract/FREE Full Text
8. 8.↵
   1. Cairncross JG,
   2. Ueki K,
   3. Zlatescu MC,
   4. et al

   . Specific genetic predictors of chemotherapeutic response and survival in patients with anaplastic oligodendrogliomas. J Natl Cancer Inst 1998; 90: 1473–79

   Abstract/FREE Full Text
9. 9.↵
   1. Law M,
   2. Oh S,
   3. Johnson G,
   4. et al

   . Perfusion magnetic resonance imaging predicts patient outcome as an adjunct to histopathology: a second reference standard in the surgical and nonsurgical treatment of low-grade gliomas. Neurosurgery 2006; 58: 1099–107

   CrossRefPubMedWeb of Science
10. 10.↵
    1. Leon SP,
    2. Folkerth RD,
    3. Black PM

    . Microvessel density is a prognostic indicator for patients with astroglial brain tumors. Cancer 1996; 77: 362–72

    CrossRefPubMedWeb of Science
11. 11.↵
    1. Li VW,
    2. Folkerth RD,
    3. Watanabe H,
    4. et al

    . Microvessel count and cerebrospinal fluid basic fibroblast growth factor in children with brain tumours. Lancet 1994; 344: 82–86

    CrossRefPubMedWeb of Science
12. 12.↵
    1. Weidner N

    . Intratumor microvessel density as a prognostic factor in cancer. Am J Pathol 1995; 147: 9–19

    PubMedWeb of Science
13. 13.↵
    1. Cha S,
    2. Johnson G,
    3. Wadghiri YZ,
    4. et al

    . Dynamic, contrast-enhanced perfusion MRI in mouse gliomas: correlation with histopathology. Magn Reson Med 2003; 49: 848–55

    CrossRefPubMedWeb of Science
14. 14.↵
    1. Aronen HJ,
    2. Pardo FS,
    3. Kennedy DN,
    4. et al

    . High microvascular blood volume is associated with high glucose uptake and tumor angiogenesis in human gliomas. Clin Cancer Res 2000; 6: 2189–200

    Abstract/FREE Full Text
15. 15.↵
    1. Plate KH,
    2. Breier G,
    3. Weich HA,
    4. et al

    . Vascular endothelial growth factor is a potential tumour angiogenesis factor in human gliomas in vivo. Nature 1992; 359: 845–48

    CrossRefPubMedWeb of Science
16. 16.↵
    1. Shweiki D,
    2. Itin A,
    3. Soffer D,
    4. et al

    . Vascular endothelial growth factor induced by hypoxia may mediate hypoxia-initiated angiogenesis. Nature 1992; 359: 843–45

    CrossRefPubMedWeb of Science
17. 17.↵
    1. Bhujwalla ZM,
    2. Artemov D,
    3. Natarajan K,
    4. et al

    . Reduction of vascular and permeable regions in solid tumors detected by macromolecular contrast magnetic resonance imaging after treatment with antiangiogenic agent TNP-470. Clin Cancer Res 2003; 9: 355–62

    Abstract/FREE Full Text
18. 18.↵
    1. Raatschen HJ,
    2. Simon GH,
    3. Fu Y,
    4. et al

    . Vascular permeability during antiangiogenesis treatment: MR imaging assay results as biomarker for subsequent tumor growth in rats. Radiology 2008; 247: 391–99

    CrossRefPubMedWeb of Science
19. 19.↵
    1. Provenzale JM,
    2. Mukundan S,
    3. Dewhirst M

    . The role of blood-brain barrier permeability in brain tumor imaging and therapeutics. AJR Am J Roentgenol 2005; 185: 763–67

    PubMed
20. 20.↵
    1. Johnson JA,
    2. Wilson TA

    . A model for capillary exchange. Am J Physiol 1966; 210: 1299–303

    FREE Full Text
21. 21.↵
    1. Purdie TG,
    2. Henderson E,
    3. Lee TY

    . Functional CT imaging of angiogenesis in rabbit VX2 soft-tissue tumour. Phys Med Biol 2001; 46: 3161–75

    CrossRefPubMed
22. 22.↵
    1. Lee TY,
    2. Purdie TG,
    3. Stewart E

    . CT imaging of angiogenesis. Q J Nucl Med 2003; 47: 171–87

    PubMedWeb of Science
23. 23.↵
    1. St Lawrence KS,
    2. Lee TY

    . An adiabatic approximation to the tissue homogeneity model for water exchange in the brain: I. Theoretical derivation. J Cereb Blood Flow Metab 1998; 18: 1365–77

    CrossRefPubMed
24. 24.↵
    1. Lev MH,
    2. Ozsunar Y,
    3. Henson JW,
    4. et al

    . Glial tumor grading and outcome prediction using dynamic spin-echo MR susceptibility mapping compared with conventional contrast-enhanced MR: confounding effect of elevated rCBV of oligodendrogliomas [corrected]. AJNR Am J Neuroradiol 2004; 25: 214–21

    Abstract/FREE Full Text
25. 25.↵
    1. Law M,
    2. Yang S,
    3. Wang H,
    4. et al

    . Glioma grading: sensitivity, specificity, and predictive values of perfusion MR imaging and proton MR spectroscopic imaging compared with conventional MR imaging. AJNR Am J Neuroradiol 2003; 24: 1989–98

    Abstract/FREE Full Text
26. 26.↵
    1. Jain R,
    2. Gutierrez J,
    3. Narang J,
    4. et al

    . In vivo correlation of tumor blood volume and permeability with histological and molecular angiogenic markers in gliomas. AJNR Am J Neuroradiol. 2011; 32: 388–94

    Abstract/FREE Full Text
27. 27.↵
    1. Kumar AJ,
    2. Leeds NE,
    3. Fuller GN,
    4. et al

    . Malignant gliomas: MR imaging spectrum of radiation therapy- and chemotherapy-induced necrosis of the brain after treatment. Radiology 2000; 217: 377–84

    CrossRefPubMedWeb of Science
28. 28.↵
    1. Chernov M,
    2. Hayashi M,
    3. Izawa M,
    4. et al

    . Differentiation of the radiation-induced necrosis and tumor recurrence after gamma knife radiosurgery for brain metastases: importance of multi-voxel proton MRS. Minim Invasive Neurosurg 2005; 48: 228–34

    CrossRefPubMedWeb of Science
29. 29.↵
    1. Langleben DD,
    2. Segall GM

    . PET in differentiation of recurrent brain tumor from radiation injury. J Nucl Med 2000; 41: 1861–67

    Abstract/FREE Full Text
30. 30.↵
    1. Covarrubias DJ,
    2. Rosen BR,
    3. Lev MH

    . Dynamic magnetic resonance perfusion imaging of brain tumors. Oncologist 2004; 9: 528–37

    Abstract/FREE Full Text
31. 31.↵
    1. Jain R,
    2. Scarpace L,
    3. Ellika S,
    4. et al

    . First-pass perfusion computed tomography: initial experience in differentiating recurrent brain tumors from radiation effects and radiation necrosis. Neurosurgery 2007; 61: 778–86, discussion 786–87

    PubMedWeb of Science
32. 32.↵
    1. Kamiryo T,
    2. Lopes MB,
    3. Kassell NF,
    4. et al

    . Radiosurgery-induced microvascular alterations precede necrosis of the brain neuropil. Neurosurgery 2001; 49: 409–14, discussion 414–15

    CrossRefPubMedWeb of Science
33. 33.↵
    1. Barajas RF Jr.,
    2. Chang JS,
    3. Segal MR,
    4. et al

    . Differentiation of recurrent glioblastoma multiforme from radiation necrosis after external beam radiation therapy with dynamic susceptibility-weighted contrast-enhanced perfusion MR imaging. Radiology 2009; 253: 486–96

    CrossRefPubMedWeb of Science
34. 34.↵
    1. Barajas RF,
    2. Chang JS,
    3. Sneed PK,
    4. et al

    . Distinguishing recurrent intra-axial metastatic tumor from radiation necrosis following gamma knife radiosurgery using dynamic susceptibility-weighted contrast-enhanced perfusion MR imaging. AJNR Am J Neuroradiol 2009; 30: 367–72

    Abstract/FREE Full Text
35. 35.↵
    1. Jain R,
    2. Narang J,
    3. Schultz L,
    4. et al

    . Permeability estimates in histopathology proven treatment induced necrosis using perfusion CT: can these add to other perfusion parameters in differentiating from recurrent/progressive tumors? AJNR Am J Neuroradiol. 2011; 32: 658–63

    Abstract/FREE Full Text
36. 36.↵
    1. Sugita Y,
    2. Terasaki M,
    3. Shigemori M,
    4. et al

    . Acute focal demyelinating disease simulating brain tumors: histopathologic guidelines for an accurate diagnosis. Neuropathology 2001; 21: 25–31

    CrossRefPubMedWeb of Science
37. 37.↵
    1. Annesley-Williams D,
    2. Farrell MA,
    3. Staunton H,
    4. et al

    . Acute demyelination, neuropathological diagnosis, and clinical evolution. J Neuropathol Exp Neurol 2000; 59: 477–89

    PubMedWeb of Science
38. 38.↵
    1. Zagzag D,
    2. Miller DC,
    3. Kleinman GM,
    4. et al

    . Demyelinating disease versus tumor in surgical neuropathology: clues to a correct pathological diagnosis. Am J Surg Pathol 1993; 17: 537–45

    CrossRefPubMedWeb of Science
39. 39.↵
    1. Graham DI,
    2. Lantos PL

    1. Prineas JW,
    2. MacDonald WI

    . Demyelinating diseases. In: Graham DI, Lantos PL. eds. Greenfield's Neuropathology. 6th ed. London, UK: Oxford University Press; 1997:814–46
40. 40.↵
    1. Jain R,
    2. Ellika S,
    3. Lehman NL,
    4. et al

    . Can permeability measurements add to blood volume measurements in differentiating tumefactive demyelinating lesions from high grade gliomas using perfusion CT? J Neurooncol 2010; 97: 383–88

    CrossRefPubMed
41. 41.↵
    1. Yankeelov TE,
    2. Rooney WD,
    3. Huang W,
    4. et al

    . Evidence for shutter-speed variation in CR bolus-tracking studies of human pathology. NMR Biomed 2005; 18: 173–85

    CrossRefPubMedWeb of Science
42. 42.↵
    1. Conturo TE,
    2. Akbudak E,
    3. Kotys MS,
    4. et al

    . Arterial input functions for dynamic susceptibility contrast MRI: requirements and signal options. J Magn Reson Imaging 2005; 22: 697–703

    CrossRefPubMed
43. 43.↵
    1. Boxerman JL,
    2. Schmainda KM,
    3. Weisskoff RM

    . Relative cerebral blood volume maps corrected for contrast agent extravasation significantly correlate with glioma tumor grade, whereas uncorrected maps do not. AJNR Am J Neuroradiol 2006; 27: 859–67

    Abstract/FREE Full Text
44. 44.↵
    1. Johnson G,
    2. Wetzel SG,
    3. Cha S,
    4. et al

    . Measuring blood volume and vascular transfer constant from dynamic, T(2)*-weighted contrast-enhanced MRI. Magn Reson Med 2004; 51: 961–68

    CrossRefPubMed
45. 45.↵
    1. Uematsu H,
    2. Maeda M

    . Double-echo perfusion-weighted MR imaging: basic concepts and application in brain tumors for the assessment of tumor blood volume and vascular permeability. Eur Radiol 2006; 16: 180–86

    CrossRefPubMed
46. 46.↵
    1. Hara AK,
    2. Paden RG,
    3. Silva AC,
    4. et al

    . Iterative reconstruction technique for reducing body radiation dose at CT: feasibility study. AJR Am J Roentgenol 2009; 193: 764–71

    CrossRefPubMedWeb of Science